Will COVID-19 infection result in increased diagnosis of Multiple Sclerosis?

A plethora of news articles on brain damage in COVID-19 patients released yesterday reported the findings of Paterson et al. in a shocking study released on July 8. The study discussed the observations of high levels of acute disseminated encephalomyelitis (ADEM) together with brain hemorrhage (bleeding) in COVID-19 patients. The authors also noted that the brain complications were not related to the respiratory severity in in COVID-19 disease [1].

A separate study from China published in June found 36% (78/214) COVID-19 patients displayed neurological disorders involving the central and peripheral nervous systems, with symptoms including dizziness, headache, impaired consciousness, seizures, taste and smell impairments, vision impairment and nerve pain [2]. To date, even though there is an impressive reduction of deaths from COVID-19, the long-term implications of COVID-19 infection is anything but clear.

In my July 1 video, I talked about how COVID-19 is no longer a respiratory disease but a blood vessel disease, and that CD147 dysregulation as result of spike protein binding can cause CNS dysfunctions [3]. So what is ADEM and how is it related to COVID-19?

ADEM is a condition where widespread inflammation in the brain and spinal cord damages the protective…